[go: up one dir, main page]

TWI874925B - 癌症治療 - Google Patents

癌症治療 Download PDF

Info

Publication number
TWI874925B
TWI874925B TW112109467A TW112109467A TWI874925B TW I874925 B TWI874925 B TW I874925B TW 112109467 A TW112109467 A TW 112109467A TW 112109467 A TW112109467 A TW 112109467A TW I874925 B TWI874925 B TW I874925B
Authority
TW
Taiwan
Prior art keywords
erdafitinib
treatment
serum phosphate
cancer
specifically
Prior art date
Application number
TW112109467A
Other languages
English (en)
Chinese (zh)
Other versions
TW202402290A (zh
Inventor
金姆 史戴肯斯
璜斯 佩雷斯路斯歐
彼得 迪波雷
安潔莉 阿凡德哈尼
尤哈恩 羅莉特
瑞迪卡 艾蓮恩 西克爾
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI874925(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202402290A publication Critical patent/TW202402290A/zh
Application granted granted Critical
Publication of TWI874925B publication Critical patent/TWI874925B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G01N33/575—
    • G01N33/57585—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
TW112109467A 2017-02-06 2018-02-02 癌症治療 TWI874925B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
US62/455,211 2017-02-06
EP17209098.7 2017-12-20
EP17209098 2017-12-20

Publications (2)

Publication Number Publication Date
TW202402290A TW202402290A (zh) 2024-01-16
TWI874925B true TWI874925B (zh) 2025-03-01

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112109467A TWI874925B (zh) 2017-02-06 2018-02-02 癌症治療

Country Status (26)

Country Link
US (2) US11077106B2 (da)
EP (2) EP3576740B1 (da)
JP (3) JP2020505425A (da)
KR (2) KR20250069693A (da)
CN (1) CN110198716A (da)
AU (2) AU2018216969B2 (da)
BR (1) BR112019016043A2 (da)
CA (1) CA3049737A1 (da)
DK (1) DK3576740T3 (da)
ES (1) ES2953005T3 (da)
FI (1) FI3576740T3 (da)
HR (1) HRP20230697T1 (da)
HU (1) HUE062453T2 (da)
IL (1) IL268463A (da)
JO (1) JOP20190190A1 (da)
LT (1) LT3576740T (da)
MX (2) MX2019009304A (da)
NZ (2) NZ796822A (da)
PH (1) PH12019501885A1 (da)
PL (1) PL3576740T3 (da)
RS (1) RS64778B1 (da)
SG (2) SG11201907199QA (da)
SI (1) SI3576740T1 (da)
SM (1) SMT202300233T1 (da)
TW (1) TWI874925B (da)
UA (1) UA126336C2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037920B1 (ru) 2014-09-26 2021-06-07 Янссен Фармацевтика Нв Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
WO2020165181A1 (en) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Cancer treatment
EP4548935A3 (en) * 2019-03-29 2025-08-06 JANSSEN Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP7747521B2 (ja) * 2019-03-29 2025-10-01 ヤンセン ファーマシューティカ エヌ．ベー． 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JOP20220182A1 (ar) * 2020-02-12 2023-01-30 Janssen Pharmaceutica Nv مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 , C HIERRO, et al., "Fibroblast growth factor (FGF) receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors", Seminars in Oncology, 42(6), Elsevier, 2015: 801~819. *
期刊 , J TABERNERO, et al., "Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors", Journal of Clinical Oncology, 33(30), ASCO, 2015: 3401~3408.; *

Also Published As

Publication number Publication date
LT3576740T (lt) 2023-08-10
ES2953005T3 (es) 2023-11-07
SI3576740T1 (sl) 2023-10-30
UA126336C2 (uk) 2022-09-21
MX2019009304A (es) 2019-09-19
MX2022007955A (es) 2022-07-27
JP2025024064A (ja) 2025-02-19
HUE062453T2 (hu) 2023-11-28
JOP20190190A1 (ar) 2019-08-04
NZ796822A (en) 2025-12-19
SG10202105110VA (en) 2021-06-29
NZ755301A (en) 2025-12-19
BR112019016043A2 (pt) 2020-03-31
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
EP4286005A3 (en) 2024-03-06
AU2018216969A1 (en) 2019-07-25
HRP20230697T1 (hr) 2023-10-13
PH12019501885A1 (en) 2020-06-29
CA3049737A1 (en) 2018-08-09
US20220110935A1 (en) 2022-04-14
EP4286005A2 (en) 2023-12-06
KR20190110581A (ko) 2019-09-30
IL268463A (en) 2019-09-26
JP2020505425A (ja) 2020-02-20
SG11201907199QA (en) 2019-09-27
RS64778B1 (sr) 2023-11-30
US11077106B2 (en) 2021-08-03
AU2024201871A1 (en) 2024-04-11
PL3576740T3 (pl) 2023-09-11
JP2023022190A (ja) 2023-02-14
CN110198716A (zh) 2019-09-03
EP3576740A1 (en) 2019-12-11
EP3576740B1 (en) 2023-06-14
JP7668777B2 (ja) 2025-04-25
SMT202300233T1 (it) 2023-09-06
AU2018216969B2 (en) 2024-04-11
FI3576740T3 (fi) 2023-08-31
DK3576740T3 (da) 2023-07-24
US20200022976A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
TWI874925B (zh) 癌症治療
TWI798199B (zh) 癌症治療
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
JP2026016402A (ja) 癌治療
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
US20220054484A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40103983A (en) Cancer treatment
HK40013982A (en) Cancer treatment
HK40018978A (en) Cancer treatment
HK40018978B (en) Cancer treatment
WO2022171064A1 (zh) 烟酰胺及含有其的组合物的制药用途
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma